

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person* <u>MCENANY PATRICK J</u>  (Last) (First) (Middle) <u>355 ALHAMBRA CIRCLE, SUITE 801</u>  (Street) <u>CORAL FL 33134</u>  (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>CATALYST PHARMACEUTICALS, INC.</u> [ <u>CPRX</u> ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director 10% Owner Officer (give title below) <input checked="" type="checkbox"/> Other (specify below) <u>Chairman of Board of Directors</u>
	3. Date of Earliest Transaction (Month/Day/Year) <u>11/13/2024</u>	
4. If Amendment, Date of Original Filed (Month/Day/Year)		

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common stock, par value \$0.001 per share	11/13/2024		M		92,500	A	\$3.54	4,570,669	D	
Common stock, par value \$0.001 per share	11/13/2024		S		92,500 <sup>(1)</sup>	D	\$22.978 <sup>(2)</sup>	4,478,169	D	
Common stock, par value \$0.001 per share	11/14/2024		M		44,655	A	\$3.54	4,522,824	D	
Common stock, par value \$0.001 per share	11/14/2024		S		44,655 <sup>(1)</sup>	D	\$21.752 <sup>(3)</sup>	4,478,169	D	

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	V	(A)	(D)	Date Exercisable	Expiration Date						Title
Options to purchase common stock	\$3.54	11/13/2024		M		92,500		(4)	05/29/2025	Common Stock	92,500	\$0	2,008,245	D	
Options to purchase common stock	\$3.54	11/14/2024		M		44,655		(4)	05/29/2025	Common Stock	44,655	\$0	1,963,590	D	

**Explanation of Responses:**

- Shares were sold for personal reasons, including paying federal income taxes and diversifying the Reporting Person's portfolio. Shares were not sold as a result of any disagreement with the Company. Mr. McEnany remains the non-executive chairman of the Company's Board of Directors and the Company's largest individual, non-institutional shareholder.
- Represents a weighted average price for the shares sold. Shares were sold in various lots ranging from \$22.82 to \$23.13 per share.
- Represents a weighted average price for the shares sold. Shares were sold in various lots ranging from \$21.52 to \$22.20 per share.
- Options vested in three equal tranches on May 29, 2019, 2020 and 2021.

/s/ Patrick J. McEnany 11/15/2024  
 \*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.